-
-
-
-
-
-
-
Summit Therapeutics (SMMT) Tops Q1 EPS by 4c
-
-
-
-
-
-
-
Citizens Highlights Summit’s (SMMT) Ivonescimab Superiority, Reiterates at Outperform
-
-
-
-
-
-
-
TD Cowen on Summit Therapeutics plc (SMMT): 'Stat Sig Overall Survival In Akeso's HARMONi-A Bodes Well For Summit's HARMONi'
-
-
-
-
-
-
-
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025
-
-
-
-
-
-
-
Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024
-
-
-
-
-
-
-
Illumina (ILMN) appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer
-
-
-
-
-
-
-
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023
-
1,208,019 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

